Every 10-Q that TuHURA Biosciences, Inc. (HURA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow HURA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HURA filings page.
TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company developing three main technologies, led by IFx-2.0, an innate immune agonist in a Phase 3 registration trial for Merkel cell carcinoma using the FDA’s accelerated approval pathway. The company is also preparing a Phase 1b/2 trial for TBS-2025, a VISTA-inhibiting antibody for mutNPM1 acute myeloid leukemia, and advancing Delta Opioid Receptor–targeted ADCs.
For the six months ended June 30, 2026, TuHURA reported a net loss of $16.8 million and no product revenue, driven mainly by $11.9 million in research and development and $4.4 million in general and administrative expenses. Cash used in operating activities was $13.0 million. As of June 30, 2026, the company had $1.0 million in cash and cash equivalents, total assets of $31.7 million, and an accumulated deficit of $157.9 million.
Liquidity is supported by a new $50 million revolving credit facility with Parkview, of which $3.6 million had been drawn by June 30 and approximately $5.8 million by mid-August 2026, plus an at-the-market equity program and prior equity offerings. Management expects existing capital resources, together with anticipated credit facility drawdowns, to fund planned operations into the end of 2028.
TuHURA Biosciences, Inc. reported a net loss of $7.5 million for the three months ended March 31, 2026, compared with $6.7 million a year earlier, as it continued to invest in its cancer immunotherapy pipeline.
Research and development expenses rose to $5.2 million, driven by IFx‑2.0 Phase 3 work, TBS‑2025 development and higher headcount, while general and administrative costs were $2.3 million. The company had $6.3 million in cash and cash equivalents and used $4.4 million in operating cash during the quarter.
TuHURA closed earlier equity financings and established a $50 million revolving credit facility with Parkview Holdings One LLC, plus a $50 million at‑the‑market equity program. Management states that existing capital resources and expected credit facility access should fund planned operations into the end of 2028 as it advances IFx‑2.0 and TBS‑2025 through clinical development.
TuHURA Biosciences (HURA) reported a larger quarterly loss and flagged liquidity risk. For Q3 2025, net loss was $7.1 million as research and development reached $5.0 million and general and administrative expenses were $1.8 million. Cash and cash equivalents were $2.7 million at September 30, 2025.
The company closed the Kineta acquisition on June 30, recording $13.6 million of goodwill and $8.3 million of in‑process R&D tied to TBS‑2025. In June, TuHURA raised approximately $12.6 million via a private placement of 4,759,309 shares and the same number of warrants at a $3.3125 exercise price; $0.5 million of the deferred tranche remained as of quarter‑end. A resale registration for those securities became effective on September 26.
Management disclosed substantial doubt about continuing as a going concern. Operating cash outflow was $22.1 million for the first nine months of 2025. Subsequent events include a secured bridge loan of up to $3.0 million at 3% (initial $1.5 million funded) and filing of a $50 million at‑the‑market program that awaits SEC effectiveness. Shares outstanding were 51,258,085 as of November 12, 2025.